Thomson D.,GlycoMar Ltd |
Bavington C.D.,GlycoMar Ltd
Carbohydrate Polymers | Year: 2012
The contamination of heparin in 2008 brought to the attention of health authorities an urgent need for structural characterisation of low molecular weight heparins and other glycosaminoglycans (GAGs) intended for clinical applications. Potentially harmful compounds can be introduced into these preparations as contaminants of the original material or as by-products of the depolymerisation process. Radical depolymerisation is one of the methods used for fractionations of GAGs. We report here on the results of the Fenton-type radical depolymerisation of dermatan sulfate (DS) by hydrogen peroxide in the presence of Cu 2+ cations. A low molecular fraction of the reaction mixture was investigated by a combination of 2D 1H, 13C HSQC, 2D HSQC-TOCSY and 2D HMBC experiments at 800 MHz. The analysis of the spectra revealed the formation of oligosaccharides with structures corresponding to the native DS sequence and containing almost exclusively GalNAc4S as the reducing end monosaccharide. In addition, oligosaccharides containing a C-4 sulfated N-acetylgalactosaminic acid in place of the reducing end GalNAc4S were identified. This open chain monosaccharide represents a non-native DS structure. © 2011 Elsevier Ltd. All rights reserved.
Agency: European Commission | Branch: FP7 | Program: BSG-SME | Phase: SME-1 | Award Amount: 1.47M | Year: 2011
The project aims to continue with some exciting work following up a development in delivering active agents to bivalve molluscs through micro-encapsulation. The early work showed that bacteria with a potential in vitro to break down some algal toxins could be effectively delivered to the gut of the bivalve. The size and nature of the micro-capsule (bead) was shown to be key. The SMEs and Other industry partners in the consortium have assempled a group of leading researchers in the field to develop this work , further, and to look into not only active detoxification but more effective depuration using pro-biotics. The group alsp plan to investigate the use of the beads as carriers of active agents to aid an immunostimulant response against attack by the Bonamia parasite on European (flat) Oysters.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 24.75K | Year: 2011
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2007-1.4-7 | Award Amount: 3.98M | Year: 2009
Current technology to control embryonic and adult stem cell behaviour is dependent on conventional in vitro culture systems and crude factors such as serum and purified proteins, often sourced from vertebrate animal tissue. These factors contribute to variations in cell properties and differentiation potential which impact on the efficacy of cell culture. More worryingly these factors are potential avenues for the introduction of unknown or known pathogens with the capacity to infect transplant recipients thereby becoming communicable to the general population. Especially concerning is the opportunity for transmission of potentially lethal diseases across vertebrate species for which there are no known cures. The propensity of primitive stem cell populations to spontaneously differentiate is an added challenge which generally necessitates cumbersome manipulation of cells by skilled operators involving daily assessment, media replenishment and or cell passaging by physical dissociation. Realising the promise of stem cells and their derivatives for clinical and industrial applications therefore requires the evolution of new paradigms for cell culture which maximise chemical definition, minimise the involvement of skilled operators, and offer non-invasive modulation of cells by biocompatible means. The aim of this proposal is to discover and integrate with established and new cell culture technology, synthetic and non-vertebrate derived purified molecules with a capacity to mimic the functional properties of crude biological reagents currently used to control the behaviour of embryonic and adult stem cells, most notably affecting self-renewal, pluripotency, lineage specification and stability following cryopreservation. These will be validated to deliver new culture paradigms designed for compliance with Good Manufacturing Practice Standards necessary for the delivery of clinical grade cells for therapeutic use.
Glycomar Ltd | Date: 2013-05-13
There is provided a composition comprising a polysaccharide obtainable from the microalgae, Prasinococcus capsulatus and strains related to P. capsulatus for use prophylactically and/or therapeutically in the treatment of disorders of the immune system, for example in psoriasis and dermatological conditions, internal immune system disorders, in particular gut inflammatory conditions and respiratory conditions. Further, there is provided derivatives of a polysaccharide obtainable from the microalgae, Prasinococcus capsulatus or an algal strain related to P. capsulatus and the use of such derivatives prophylactically and/or therapeutically in the treatment of disorders of the immune system.
Glycomar Ltd | Date: 2016-08-24
There is provided a composition comprising a polysaccharide obtainable from the microalgae, Prasinococcus capsulatus and strains related to P. capsulatus for use in the treatment of disorders of the immune system, for example in psoriasis and dermatological conditions, internal immune system disorders, in particular gut inflammatory conditions and respiratory conditions. Further, there is provided derivatives of a polysaccharide obtainable from the microalgae, Prasinococcus capsulatus or an algal strain related to P. capsulatus and the use of such derivatives in the treatment of disorders of the immune system.
Agency: GTR | Branch: Innovate UK | Program: | Phase: European | Award Amount: 141.89K | Year: 2013
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 192.85K | Year: 2016
The project’s goal is to provide a novel sugar replacement ingredient to the global food market. The ingredient is a specialist carbohydrate sustainably manufactured from a marine microalgae. The project will demonstrate new technology at industrial pilot scale to grow microalgae and purify the product from the microalgae cultures. The project brings together Glycomar Ltd (UK), an SME company specialising in the discovery and development of novel polysaccharide products, MicroA AS (Norway) an SME company specialising in technology for production of microalgae, and a market leading food company. These partners bring together the right skills to develop a game changing sugar replacement product, which will improve the health profile of confectionery and other foods.
Agency: European Commission | Branch: H2020 | Program: SME-1 | Phase: SMEInst-05-2016-2017 | Award Amount: 71.43K | Year: 2016
Atopic dermatitis (AD), a chronic inflammatory skin disease characterised by itchy skin lesions and rashes, affects 1 child in 5-10, and 3% of adults. Without effective treatment it can have a severe negative impact on quality of life. Treatment has historically been dominated by topical steroid creams, although consumers reticent to using steroids over long periods, and for convenience (some steroid treatments are prescription only) are increasingly opting for non-pharma products with natural attributes. These natural products, however, tend to have high toxicity and therefore to create unpleasant side effects. Glycomars eczema treatment, Fucoderm, directly addresses these shortcomings and responds to consumer preferences. Using an active pharmaceutical ingredient extracted from brown seaweed a Fucoidan Glycomar has created a novel topical formulation for maintenance treatment. The product is the first commercial application of Glycomars extensive glycobiology expertise the team has over 100 years collective experience in marine biotechnology and drug discovery/development and it will be targeted towards mild- to moderate AD sufferers. Together these cases comprise 80-90% of the 4b market, which is growing at 3,8% maximising potential impact. The company, which has been working for 10 years in pursuit of novel immunomodulatory saccharides, has a track record of attracting non-dilutive grant funding, and of creating cash generative, value enhancing partnerships. Successful commercialisation of Fucoderm would enable Glycomar to meet its target of reaching profitability by 2019, in turn facilitating the launch of other consumer healthcare, nutraceutical and cosmetic products in the development pipeline.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 42.48K | Year: 2012
GlycoMar Limited, a biotechnology company based in Scotland, and MicroA AS, a microalgae and photobioreactor (PBR) technology company based in Norway, are proposing a feasibility project to evaluate the pilot scale production of an identified high value cosmetic ingredient from a marine microalga. The project will use MicroA’s recently patented PBR technology as the scale-up platform for GlycoMar’s microalgal polysaccharide product development. MicroA will use their pilot scale system (200 litres) to optimise growth conditions for maximum algal polysaccharide production. GlycoMar will optimise downstream processing to maximise recovery of the target product. The project will establish the commercial viability of full-scale production. Success of the project will be an important milestone for both partner companies and the wider biotechnology and microalgae industries, and will lead to commercialisation as a high value natural skin care ingredient within 3 years.